In this issue:
Neoadjuvant chemotherapy + nivolumab ± ipilimumab in operable NSCLC
Sotorasib vs. docetaxel for previously treated KRASG12C-mutated NSCLC
Adjuvant icotinib for resected EGFRmutated stage IB NSCLC
First-line lorlatinib vs. crizotinib for advanced, ALK-positive NSCLC
Bintrafusp alfa in ICI-resistant/refractory NSCLC
Adjuvant osimertinib for resected EGFRmutated stage IB–IIIA NSCLC
Durvalumab after chemoradiotherapy in unresectable stage III NSCLC with uncommon alterations
First-line chemotherapy ± nivolumab + ipilimumab in metastatic NSCLC
Survival trends in advanced NSCLC after introduction of immunotherapy
Durvalumab after chemoradiotherapy in unresectable stage III EGFR-mutant NSCLC
Please login below to download this issue (PDF)